 |
|
|
|
| Strategy |
| |
Orient Europharma shall continue to capitalize on its core strengths: pharmaceuticals, infant nutrition and food supplements for the elderly, Oncology and Dermo-cosmetics. OE shall also expand into emerging market opportunities resulting from the following macro and micro environmental changes: |
| |
-
The growth of geriatric, pediatric, and OBS/GYN markets due to population factors as well as the inclusion of the elderly, children and housewives into taiwan's National Health Insurance (NHI) Plan coverage.
-
The resurgence of general practitioners (GPs) due to the implementation of the Medical Referral System and the current separation of prescription and dispensing under the NHI.
-
The growht of the "over-the-counter" (OTC) market due to:
- OTC reclassification.
- Increasing health-consciousness and the trend toward self-medication among consumers.
- The rise in OTC drugstore chains at the retail level.
|
Orient Europharma has redefined itself as a professional pharmaceuticals and nutritional company, expanding its business domain to cover the R&D of pharmaceuticals, niche-oriented generic products, Dermo-cosmetics, OTC products and general baby-care products.
As a biotech company, OE will continue to invest in niche breakthrough products to improve the quality of life and health of the people in the Asia-Pacific region.
OE's market currently includes Taiwan, Singapore, Malaysia, Hong Kong, Macao, Philippines and China. OE is planning to futher expand its business to other Asian countries. |
| |
  |
| |
|
|
 |
|
 |
|
| |
Malaysia
Orient Europharma (M) Sdn Bhd
33, Jalan U1/30, Seksyen U1,
40150 Shah Alam,
Selangor,
Malaysia.
Tel: 03 5569 5405
Fex: 03 5569 5404
Email: enquiry@karihome.com.my |
|
| |
|
 |
|
| |
|
 |
|
|
| |
|
|
 |
|
|
| |
|
|
 |
|
|
| |
|
|
|
